Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Baxter
Express Scripts
Johnson and Johnson
Medtronic

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR NALIDIXIC ACID


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nalidixic Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00741052 ↗ Ciprofloxacin Multiple Dose for Adult Cholera Completed International Centre for Diarrhoeal Disease Research, Bangladesh Phase 3 2007-07-01 Cholera is an important diarrhoeal disease and an important cause of death, particularly during epidemic outbreaks, in Bangladesh and many other developing countries. Used as an adjunct to management of dehydration, antimicrobial therapy using an appropriate agent reduces diarrhoea duration and stool volume in severe cholera by about half. The usefulness of antimicrobials has, however, been greatly eroded by the increasing prevalence of resistant strains of V. cholerae O1. From October 2004 at the Matlab Hospital and from December 2004 at the Dhaka Hospital of ICDDR, B, V. cholerae strains became increasingly resistant to tetracycline and erythromycin- two drugs used in the treatment of severe cholera in adults and children respectively. Because of this high prevalence of resistance we resorted in early 2005 to using ciprofloxacin for treatment against multi drug resistant V. cholerae. Although all isolates were susceptible to ciprofloxacin when standard thresholds for disc-diffusion or E-test were used, but majority of the strains demonstrated a MIC value of 0.250 µg/ml, over hundred-folds greater than the V. cholerae strains tested in earlier years, which generally had a MIC of <0.003 µg/ml. In this randomized, double blind, controlled trial we will assess clinical and bacteriological response to 12 hourly oral dose of ciprofloxacin for 3 days in which the first two doses will be 1 g each and the later 4 doses will be 500 mg each, and compare them with a single 1 g oral dose of azithromycin. We are using azithromycin as the comparator drug because current circulating V. cholerae isolates are susceptible (MIC ≤ 0.125 µg/ml) to this azithromycin, and single-dose azithromycin has been evaluated earlier to be effective in the treatment of cholera.
NCT01335334 ↗ H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Unknown status The University of Texas Health Science Center, Houston Phase 4 2011-03-01 The proposed open-label one arm before-after clinical trial will assess the efficacy of a 14-day quadruple therapy containing 420mg of bismuth subcitrate potassium, 375mg of metronidazole, 375mg of tetracycline hydrochloride (Pylera® packs from Axcan Pharma) and 20mg of omeprazole in eradicating H. pylori infection in 50 asymptomatic adults in El Paso, Texas. As part of the study we will obtain specimens for culture of H. pylori in a reference laboratory.
NCT01804634 ↗ Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Recruiting Sidney Kimmel Comprehensive Cancer Center Phase 2 2013-03-27 The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
NCT01804634 ↗ Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 2013-03-27 The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nalidixic Acid

Condition Name

Condition Name for Nalidixic Acid
Intervention Trials
H. Pylori Infection 1
H. Pylori Infection, Gastritis, Resistance and Treatment 1
H.Pylori Gastrointestinal Disease 1
H.Pylori Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nalidixic Acid
Intervention Trials
Cholera 1
Gastrointestinal Diseases 1
Gastritis 1
Digestive System Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nalidixic Acid

Trials by Country

Trials by Country for Nalidixic Acid
Location Trials
United States 6
Bangladesh 1
Greece 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nalidixic Acid
Location Trials
New York 2
Florida 1
Texas 1
North Carolina 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nalidixic Acid

Clinical Trial Phase

Clinical Trial Phase for Nalidixic Acid
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nalidixic Acid
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nalidixic Acid

Sponsor Name

Sponsor Name for Nalidixic Acid
Sponsor Trials
International Centre for Diarrhoeal Disease Research, Bangladesh 1
The University of Texas Health Science Center, Houston 1
Sidney Kimmel Comprehensive Cancer Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nalidixic Acid
Sponsor Trials
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.